Please login to the form below

Not currently logged in
Email:
Password:

New head of Lilly oncology

Eli Lilly has appointed Sue Mahony to the role of senior vice president and president of Lilly Oncology

Sue Mahony, currently senior vice president of human resources and diversity, is to become senior vice president and president of Lilly Oncology, replacing John H Johnson, who left the company last month.

Mahony will continue to report to CEO John Lechleiter and will remain on the company's executive committee. Her new position is effective immediately.

Since his departure from Lilly, Johnson has taken over the reins at Savient Pharmaceutical, which is in the process of bringing its gout drug Krystexxa (pegloticase) to market in the US. He was previously CEO of ImClone Systems, and joined Lilly when it acquired the cancer-focused biotech company in 2008.

Steve Fry, currently vice president of human resources for bio-medicines and emerging markets, will take Mahony's old post and will join Lilly's executive leadership team. Fry was managing director of Lilly's Australian affiliate from 2004 to 2007, before becoming executive director of HR for the intercontinental region and Japan. 

Mahony, who has been with Lilly for more than 10 years, was named to the top HR position in 2009. The year before, she had been promoted to serve as general manager of Lilly, following a number of positions in the company's global marketing and new product development operations.

Before joining Lilly, she spent a decade in sales and marketing roles in the UK and Europe in oncology/hematology and cardiovascular medicine for Amgen, Bristol-Myers Squibb (BMS), and Schering-Plough. She holds a PhD in pharmacy from Aston University in the UK, and an MBA from the London Business School. 

Lilly Oncology's portfolio of marketed drugs includes the non-small cell lung cancer treatment Alimta and the ovarian cancer therapy Gemzar. The company has also declared a commitment to developing personalised cancer medications.

11th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics